BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 23, 2010
View Archived Issues
Transient Receptor Potential Channels Keep Branching Out
Read More
Aragon Raises $22M to Move 2 Cancer Drugs Into the Clinic
Read More
Earnings Roundup
Read More
Stock Movers
Read More
Clinic Roundup
Read More
Other News To Note
Read More
After Mixed Phase III, Alimera Prices $72M IPO Below Range
Four months after delivering mixed Phase III data on diabetic macular edema drug Iluvien, Alimera Sciences Inc. raised $72.1 million in its initial public offering. (BioWorld Today)
Read More
Amgen Boasts Solid Quarter; Prolia Launch on the Horizon
Read More